Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom

Executive Summary

A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.

You may also be interested in...



Galapagos CEO Interview: Independence Allows Us To Keep Innovating

Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."

Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase

Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.

Ablynx Ups Profile Stateside With $200m Nasdaq Listing

Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM000882

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel